文献速递免疫规划传染病防控与疫情报告

Tdap疫苗在四价脑膜炎球菌TT结合疫苗之前、同时或之后接种对成人朝觐者脑膜炎球菌多糖抗体应答的影响:一项随机对照试验

Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
PubMed 文献 · Vaccine · 2018-06-05

研究纳入166名18-64岁澳大利亚成人朝觐者,随机分为三组:Tdap先于MCV4+PCV13接种3-4周、三疫苗同时接种、MCV4+PCV13先于Tdap接种3-4周。结果显示先接种Tdap组W群rSBA≥4倍升高的比例显著较低,三组保护阈值达标率及GMT无差异;先接种MCV4/PCV13组在接种Tdap前抗白喉和抗破伤风抗体水平较高,接种Tdap后仅抗破伤风应答持续显著较高。无严重不良事件报告。

要点

  • 先接种Tdap组W群rSBA≥4倍升高比例显著低于其他组。
  • 三组间rSBA≥8保护阈值达标率及接种后SBA GMT无差异。
  • 先接种MCV4/PCV13组接种Tdap后仅抗破伤风应答显著较高。

核心结论

  • 朝觐者需多种疫苗接种时,Tdap与MCV4/PCV13同时接种可产生足够免疫应答并避免脑膜炎球菌免疫干扰,且单次就诊便利。
  • MCV4/PCV13后3-4周再接种Tdap具有增强破伤风类毒素应答的优势。

研究设计与样本

  • 随机对照试验,2015年招募166名18-64岁(中位42岁)澳大利亚成人朝觐者,160人完成研究。
  • 随机分为三组:组1先接种Tdap,3-4周后接种MCV4+PCV13;组2三疫苗同时接种;组3先接种MCV4+PCV13,3-4周后接种Tdap。
  • 基线、每次接种访视及接种后3-4周采血,用兔补体血清杀菌抗体(rSBA)试验检测C、W、Y群应答,ELISA检测白喉和破伤风IgG抗体;每次接种后填写症状日记。

主要发现

  • 组1(先接种Tdap)W群rSBA≥4倍升高的受试者比例显著低于其他组。
  • 三组间接种后rSBA≥8保护阈值达标率及SBA几何平均滴度(GMT)无差异。
  • 组3(先接种MCV4/PCV13)在接种Tdap前抗白喉和抗破伤风抗体水平高于其他组,接种Tdap后仅抗破伤风应答仍显著较高。
  • 未报告严重不良事件。

临床怎么用

  • 朝觐者需多种疫苗接种时,Tdap与MCV4/PCV13同时接种可产生足够免疫应答并避免脑膜炎球菌免疫干扰。
  • MCV4/PCV13后3-4周再接种Tdap具有增强破伤风类毒素应答的优势。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hajj pilgrims are susceptible to several serious infections and are required to receive multiple vaccinations. Polysaccharide-protein conjugate vaccines contain carrier proteins such as tetanus toxoid (TT), diphtheria toxoid or a mutant of diphtheria toxoid (CRM197). These carrier proteins may interact with other conjugate or combination vaccines containing tetanus or diphtheria on concurrent or sequential administration. We examined the immune interaction of separate and concomitant administration of a tetanus/diphtheria/acellular pertussis (Tdap) vaccine with a TT-conjugated quadrivalent meningococcal vaccine (MCV4) (coadministered with 13-valent pneumococcal CRM197-conjugate vaccine [PCV13]) in adult Australian pilgrims before attending Hajj in 2015. We randomly assigned each participant to one of three vaccination schedules. Group 1 received Tdap 3-4 weeks before receiving MCV4 coadministered with PCV13. Group 2 received all three vaccines concomitantly. Group 3 received MCV4 and PCV13 3-4 weeks before Tdap. Blood samples were collected at baseline, at each vaccination visit and 3-4 weeks after vaccination and tested for response to meningococcal serogroups C, W and Y using a serum bactericidal antibody (rSBA) assay with baby rabbit complement, and to diphtheria and tetanus toxoid, measuring IgG antibodies by ELISA. Participants completed symptom diaries after each vaccination. A total of 166 participants aged 18-64 (median 42) years were recruited, of whom 160 completed the study. Compared to the other groups, Group 1 (given Tdap first) had significantly lower proportion of subjects achieving a ≥4-fold rise in rSBA for serogroup W. No difference was detected across the three groups in achieving protection threshold (rSBA ≥8 post vaccination) or SBA geometric mean titre (GMT) post vaccination. Group 3, which was given MCV4/PCV13 first, had high levels of antibody against diphtheria and tetanus than the other groups, when tested prior to receipt of Tdap; Only the anti-tetanus responses remained significantly higher after Tdap administration. No serious adverse events were reported. In conclusion, when multiple vaccination is required for Hajj pilgrims, administering Tdap concurrently with MCV4/PCV13 produces adequate immune responses, and avoids meningococcal immune interference, in the convenience of a single consultation. However, giving Tdap 3-4 weeks after MCV4/PCV13 has the advantage of an enhanced tetanus toxoid response. The trial is Trials Registry (ANZCTR): ACTRN12613000536763.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tashani M, Alfelali M, Barasheed O, et al. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial. Vaccine. 2018. PMID: 29880243. doi:10.1016/j.vaccine.2018.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。